73 related articles for article (PubMed ID: 1868441)
1. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
2. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. Characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation.
Fortis C; Ferrero E; Biffi M; Heltai S; Besana C; Bucci E; Tresoldi M; Rugarli C
Cancer Immunol Immunother; 1991; 33(2):128-32. PubMed ID: 2036660
[TBL] [Abstract][Full Text] [Related]
4. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
[TBL] [Abstract][Full Text] [Related]
7. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
Itoh K; Hayakawa K; Salmeron MA; Legha SS; Murray JL; Talpaz M; Balch CM; Parkinson DR; Lee K; Zukiwski AA
Cancer Immunol Immunother; 1991; 33(4):238-46. PubMed ID: 2059968
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
Pavone L; Andrulli S; Santi R; Majori M; Buzio C
Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
[TBL] [Abstract][Full Text] [Related]
10. Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.
Vlasveld LT; van de Wiel-van Kemenade E; de Boer AJ; Sein JJ; Gallee MP; Krediet RT; Mellief CJ; Rankin EM; Hekman A; Figdor CG
Cancer Immunol Immunother; 1993; 36(3):210-3. PubMed ID: 8439983
[TBL] [Abstract][Full Text] [Related]
11. Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype.
Lotzová E; Savary CA; Freedman RS; Edwards CL; Morris M
Cancer Immunol Immunother; 1990; 31(3):169-75. PubMed ID: 2337905
[TBL] [Abstract][Full Text] [Related]
12. Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies.
Flens MJ; Mulder WM; Bril H; von Blomberg van de Flier MB; Scheper RJ; van Lier RA
Cancer Immunol Immunother; 1993 Oct; 37(5):323-8. PubMed ID: 8402736
[TBL] [Abstract][Full Text] [Related]
13. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2.
Whiteside TL; Heo DS; Takagi S; Johnson JT; Iwatsuki S; Herberman RB
Cancer Immunol Immunother; 1988; 26(1):1-10. PubMed ID: 3257898
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2.
Weidmann E; Bergmann L; Hechler P; Mitrou PS
Cancer Immunol Immunother; 1991; 33(6):398-402. PubMed ID: 1878892
[TBL] [Abstract][Full Text] [Related]
16. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas.
Cózar JM; Canton J; Tallada M; Concha A; Cabrera T; Garrido F; Ruiz-Cabello Osuna F
Cancer Immunol Immunother; 2005 Sep; 54(9):858-66. PubMed ID: 15887015
[TBL] [Abstract][Full Text] [Related]
17. Expression of aminopeptidase N/CD13 in tumour-infiltrating lymphocytes from human renal cell carcinoma.
Riemann D; Göhring B; Langner J
Immunol Lett; 1994 Sep; 42(1-2):19-23. PubMed ID: 7829125
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.
Elkord E; Burt DJ; Drijfhout JW; Hawkins RE; Stern PL
Cancer Immunol Immunother; 2008 Jun; 57(6):833-47. PubMed ID: 18004564
[TBL] [Abstract][Full Text] [Related]
19. Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion.
Toh U; Fujii T; Seki N; Niiya F; Shirouzu K; Yamana H
Cancer Immunol Immunother; 2006 Oct; 55(10):1219-27. PubMed ID: 16362409
[TBL] [Abstract][Full Text] [Related]
20. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
